ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis.

Abstract

Background:

The burden of major depressive disorder includes suffering due to symptom severity, functional impairment, and quality of life deficits. The aim of this study was to compare the differences between electroconvulsive therapy and pharmacotherapy in reducing such burdens.

Methods:

This was a pooled analysis study including 2 open-label trials for major depressive disorder inpatients receiving either standard bitemporal and modified electroconvulsive therapy with a maximum of 12 sessions or 20 mg/d of fluoxetine for 6 weeks. Symptom severity, functioning, and quality of life were assessed using the 17-item Hamilton Rating Scale for Depression, the Modified Work and Social Adjustment Scale, and SF-36. Side effects following treatment, including subjective memory impairment, nausea/vomiting, and headache, were recorded. The differences between these 2 groups in 17-item Hamilton Rating Scale for Depression, Modified Work and Social Adjustment Scale, quality of life, side effects, and time to response (at least a 50% reduction of 17-item Hamilton Rating Scale for Depression) and remission (17-item Hamilton Rating Scale for Depression ≤7) following treatment were analyzed.

Results:

Electroconvulsive therapy (n=116) showed a significantly greater reduction in 17-item Hamilton Rating Scale for Depression, Modified Work and Social Adjustment Scale, and quality of life deficits and had significantly shorter time to response/remission than fluoxetine (n=126). However, the electroconvulsive therapy group was more likely to experience subjective memory impairment and headache.

Conclusions:

Compared with fluoxetine, electroconvulsive therapy was more effective in alleviating the burden of major depressive disorder and had a substantially increased speed of response/remission in the acute phase. Increased education and information about electroconvulsive therapy for clinicians, patients, and their families and the general public is warranted.

• Authors: Ching-Hua Lin, Chun-Jen Huang, Cheng-Chung Chen
• Journal: The international journal of neuropsychopharmacology (Int J Neuropsychopharmacol) Vol. 21 Issue 1 Pg. 63-72 (01 01 2018) ISSN: 1469-5111 [Electronic] England
• PMID: 29228200 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2017. Published by Oxford University Press on behalf of CINP.

Chemical References

• Antidepressive Agents, Second-Generation
• Fluoxetine

Topics

• Adult
• Age Factors
• Antidepressive Agents, Second-Generation (therapeutic use)
• Cost of Illness
• Depressive Disorder, Major (economics, psychology, therapy)
• Electroconvulsive Therapy (methods)
• Female
• Fluoxetine (therapeutic use)
• Humans
• Male
• Middle Aged
• Outcome Assessment, Health Care
• Psychiatric Status Rating Scales
• Psychometrics
• Quality of Life
• Taiwan (epidemiology)
• Time Factors